Introduction:
Corona Virus-induced disease – 2019 (COVID-19) pandemic stimulates research works to find a solution to this crisis from starting 2020 year up to now. With ending of the 2021 year, various advances in pharmacotherapy against COVID-19 have emerged.
Regarding antiviral therapy, Casirivimab and imdevimab antibody combination is a type of new immunotherapy against COVID-19. Standard antiviral therapy against COVID-19 includes Remdesivir and Favipravir.
Aim of Study:
To compare the efficacy and safety of antibodies cocktail (casirivimab and imdevimab), Remdesivir, and Favipravir in the COVID-19 patients
Patients and Population:
265 hospitalized COVID-19 patients were used to represent the COVID-19 population and were assigned into three groups in a ratio of (1:2:2) respectively, Group (A) received REGN3048-3051(Antibodies cocktail (casirivimab and imdevimab), group (B) received remdesivir, and group (C) received favipravir.
Methods:
The study design is a single-blind non-Randomized Controlled Trial (non-RCT). The drugs of the study are owned by Mansoura University Hospital (MUH) and prescribed by chest diseases lectures of the faculty of medicine-Mansoura University. The duration of the study is about 6 months after ethical approval.
Results and discussion:
Casirivimab and imdevimab achieve less 28-day mortality rate, less mortality at hospital discharge, more negative swab cases, less need for O2 therapy and IMV, less duration of this need, less hospital and ICU stay, less case progression as presented by lower World Health Organization (WHO) scale and better multi-organ functions as presented by lower Sequential Organ Function Assessment (SOFA) score than Remdesivir and Favipravir.
Conclusion:
From all of these results, it is concluded that Group A (Casirivimab & imdevimab) has more favorable clinical outcomes than B (remdesivir) & C (favipravir) intervention groups.
Clinical Trial Registration: NCT05502081, 16/08/2022, Clinicaltrials.gov, retrospectively registered